SMILDA - Symbicort®Turbuhaler® allergan challenge study in allergic patients with mild asthma
Study identifier:D5890L00007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A comparative, placebo-controlled, double blind, double dummy, cross-over, single centre, phase IIIb study between formoterol alone (Oxis® Turbuhaler® 4.5 µg) and the fixed combination of formoterol and budesonide (Symbicort® Turbuhaler®160/4.5 µg) on airway responsiveness and airway inflammation induced by repeated low-dose allergen challenge in allergic patients with mild asthma
Medical condition
asthma
Phase
Phase 3
Healthy volunteers
No
Study drug
formoterol, budesonide/formoterol
Sex
All
Actual Enrollment
16
Study type
Interventional
Age
18 Years - 55 Years
Date
Study Start Date: 01 Oct 2004
Primary Completion Date: -
Study Completion Date: 01 May 2006
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Symbicort Medical Science Director
AstraZeneca
